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Plectin-related scapuloperoneal myopathy with
treatment-responsive myasthenic syndrome
The human plectin gene (PLEC) on chromosome 8q24
codes for a 4,684 amino acids large protein whose iso-
forms [1] are key for the functional and structural orga-
nization of filamentous cytoskeletal networks, thereby
contributing to fundamental biomechanical properties of
mechanical stress-bearing tissues [2]. Plectinopathies
thus far comprise five autosomal-recessive entities,
including epidermolysis bullosa simplex with muscular
dystrophy (EBS-MD), EBS-MD with myasthenic syn-
drome (EBS-MD-MyS), limb girdle muscular dystrophy
type 2Q, EBS with pyloric atresia, skin-only EBS and the
autosomal-dominant variant EBS-Ogna [2,3]. Herein, we
report the clinical, genetic, pathological and biochemical
findings in a Caucasian patient with late-onset scapu-
loperoneal myopathy with ephedrine-responsive myas-
thenic syndrome caused by two novel compound
heterozygous PLEC mutations. Informed consent in writ-
ing was obtained from the patient.
A 42-year-old Caucasian male presented with pro-
gressive symmetrical scapular and peroneal weakness
and atrophy starting at age 25. He first experienced epi-
sodes of concurrent fatigue, fluctuating palpebral ptosis
and diplopia, and dyspnoea in his early thirties. His past
medical history included congenital hypotonia, delayed
motor milestones and transient skin blistering limited to
his early infancy. His motor performance was similar to
his peers throughout childhood and adolescence except
for mild endurance deficits. Family history was unre-
markable. Neurological examination at the age of 36
showed external ophthalmoparesis, bilateral fluctuating
palpebral ptosis, facial weakness, arched palate, and
symmetrical and marked weakness and atrophy of the
shoulder girdle muscles with scapular winging (Fig-
ure 1A,B) along with bilateral severe foot dorsiflexion
weakness. He also presented severe weakness of his fore-
arm and knee flexor muscles, moderate weakness of his
hip flexors and extensors muscles as well as a rigid spine
with prominent lumbar lordosis. His muscle weakness
progressed, becoming a wheelchair user in his late thir-
ties. At this point, Southern blot-based genetic testing
for type 1 facioscapulohumeral muscular dystrophy
(FSHD) was performed, which yielded normal results for
D4Z4 microsatellite repeats. Creatine kinase levels were
repeatedly elevated (10x above normal upper limit). A
muscle MRI when aged 40 revealed pronounced fatty
replacements of shoulder girdle muscles, the posterior
compartment of thighs and the anterior compartment of
his lower legs (Figure 1C). Electromyography revealed a
myopathic pattern in conjunction with fibrillation
potentials, positive sharp waves and complex repetitive
discharges. Repetitive stimulation studies of the radial
nerve at 3 Hz recorded a 20% decremental response.
While oral pyridostigmine treatment alone (3 9 60 mg
per day) or in combination with 3,4-DAP (3 9 15 mg
per day, pyridostigmine reduced to 3 9 30 mg) showed
no or only a slight benefit, a sole treatment with the
sympathomimetic amine ephedrine (2 9 50 mg per
day) led to a significant improvement of ptosis, diplopia
and fatigue, and to a better score on the Myasthenia
Gravis Composite Scale with a change from 15 to 7,
especially on ocular-related items. While the further
increase in the ephedrine dose (up to 2 9 100 mg per
day) resulted in a complete remission of his myasthenic
symptoms, this improvement was accompanied by typi-
cal sympathomimetic side effects comprising tachycardia
and high blood pressure. Subsequently, the dose of ephe-
drine was reduced again to 2 9 50 mg per day and
both pyridostigmine (3 9 30 mg per day) and 3,4-DAP
(3 9 15 mg per day) were added, which led to a good
control of his myasthenic symptoms. Morphological
analysis of a diagnostic muscle biopsy taken from his
right deltoid muscle showed a myopathic pattern with a
slight increase in endo- and perimysial connective tis-
sue, rounding of muscle fibres with increased fibre-size
variability, and internalization of myonuclei (Figure 1D,
E). The latter occasionally displayed clustering of
atrophic and non-atrophic fibres. While neither degener-
ating and regenerating fibres nor rimmed vacuoles could
be detected, multiple COX-negative fibres and fibres with
rubbed-out lesions were present in combined COX/SDH
stains (Figure 1F). In comparison to normal control tis-
sue, plectin and desmin double-immunofluorescence
analysis depicted a highly pathological picture with a
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complete absence of sarcoplasmic plectin staining and a
coarsened and attenuated desmin signal pattern in all
muscle fibres (Figure 1G–L). Traces of plectin-positive
signals occasionally were detected at the level of the sar-
colemma in a subset of muscle fibres (Figure 1G).
Immunoblot analysis of total protein extracts using anti-
bodies directed against the N- and C-termini of plectin
further confirmed the nearly complete abrogation of
plectin protein expression in his skeletal muscle tissue
(Figure 1M). Sanger sequencing of the coding exons and
the conserved splice sites of the PLEC gene resulted
in the identification of two novel compound heterozy-
gous variants. One variant consisted of a maternally
inherited deletion of one nucleotide (NM_000445.3:
c.11737delC) in exon 32 leading to a frameshift and a
premature transcriptional termination 30 codons after
the mutation (p.Arg3913Valfs*30), thus potentially
yielding a protein of only 3,943 amino acids. The other
variant was a heterozygous paternally inherited muta-
tion affecting a highly conserved splice acceptor site
(NM_000445.3: c.2539-2A > G). The latter mutation
was predicted to lead to skipping of exon 21 resulting in
frameshift and consecutive premature transcriptional
termination with a resulting truncated protein of only
929 amino acids. Both truncated proteins were absent
in immunoblots indicating they were not synthesized or
were unstable (Figure 1M and data not shown). Thus,
following ACMG criteria both variants were classified as
novel, loss-of-function, disease-causing mutations. Using
a custom-designed next-generation sequencing panel
that included all known genes associated with myopa-
thies and congenital myasthenic syndromes [4], we did
not identify any pathogenic variant that segregated with
the disease except for mutations in the PLEC gene. Thus,
a genetic ‘double-trouble’ problem could be excluded in
this patient.
Myopathies presenting with scapuloperoneal pheno-
type are caused by a wide variety of mutated genes
involved in structural, enzymatic, transcriptional and
homeostatic functions. This is the first report on an
individual with adult-onset scapuloperoneal myopathy
caused by two novel compound heterozygous PLEC
mutations (c.11737delC in exon 32; c.2539-2A > G in
exon 21) which affect the expression of all four skeletal
muscle-specific plectin isoforms, subsequently causing
the pathognomonic desmin and mitochondrial pathol-
ogy in skeletal muscle tissue [5,6]. EBS-MD-MyS has
only been reported in four patients so far [7–10].
Destruction and remodelling of junctional folds of neu-
romuscular endplates were reported in one patient [8],
an observation also made in plectin knock-out mice
[11]. Notably, our patient presented with transient skin
blistering limited to his early infancy despite an almost
total absence of plectin. A possible explanation is that
minimal expression of the 3,943-amino acids protein,
not detectable by Western blotting, could lead to its
binding to the hemidesmosmal protein integrin a6b4,
which, in turn, would bind to BPAG1e and BPAG2
(collagen XVII), allowing the formation of a partially
functional hemidesmosome [12,13]. Hemidesmosome
formation, even at limited levels, might then be respon-
sible for the lack of an active skin phenotype. To date,
no specific treatment is available for plectinopathies. In
this context, it is noteworthy that a medication with
ephedrine in combination with pyridostigmine and 3,4-
diaminopyridine led to a marked improvement of myas-
thenic symptoms. It may thus serve as a symptomatic
treatment to alleviate myasthenic symptoms in EBS-
MD-MyS.
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Figure 1. Clinical, radiological, myopathological and biochemical findings in a patient with EBS-MD-MyS. Note the marked atrophy of
shoulder girdle muscles (A,B, arrowheads) and the marked fatty replacement of both peroneal muscle groups in the MRI picture of the
lower legs (C, arrowheads). The diagnostic muscle biopsy showed a myopathic pattern (D,E) in conjunction with multiple COX-negative
fibres (F, asterisks). Moreover, plectin and desmin immunostaining revealed markedly reduced signal intensities (G,H,I; normal control
J,K,L). Immunoblots of total protein extracts from a normal (C) and the diseased (P) muscle using two different antibodies (P1, guinea pig
polyclonal, C-terminal repeat domain 6 epitope, [11]; #9, rabbit polyclonal, N-terminal exons 9–12 encoded epitope [12]) directed
against plectin demonstrated a virtually absent plectin signal in the patient (M). Note that the full-length plectin signals appear at
different positions as sections of independent, immunoblotted SDS-PAGE gels are shown; (CBB) Coomassie Brilliant Blue stained SDS-
PAGE gel for loading control.
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